

COMMONWEALTH OF MASSACHUSETTS

SUFFOLK, ss.

BOARD OF REGISTRATION
IN PHARMACY

In the Matter of)	
Radioisotope Life Sciences)	Docket No.: PHA-2024-0089 &
License No. NU00023)	PHA-2024-0138
Expires: December 31, 2025)	

CONSENT AGREEMENT FOR REPRIMAND

The Massachusetts Board of Registration in Pharmacy (Board) and Radioisotope Life Sciences (Nuclear Pharmacy or Licensee), a nuclear pharmacy licensed by the Board, license no. NU00023, do hereby stipulate and agree that the following information shall be entered into and become a permanent part of the Nuclear Pharmacy's record maintained by the Board:

1. Licensee acknowledges the Board opened Complaints against its Massachusetts nuclear pharmacy license related to the conduct set forth in Paragraph 2, identified as Docket Numbers PHA-2024-0089 and PHA-2024-0138 (Complaint).
2. Licensee and the Board agree to resolve this Complaint without making any admissions or findings and without proceeding to a formal adjudicatory hearing. The Complaint alleges the following:

PHA-2024-0089

On April 12, 2024, deficiencies by Licensee were observed during a USP Nuclear Compliance inspection. Licensee failed to report an Above Action Level (AAL) event to the Board and had unlicensed staff conducting cleaning of the interior ISO 5 Primary Engineering Control (PEC), in violation of Board Policy 2023-09 and 247 Mass. Code Regs. 8.00.

PHA-2024-0138


On or about May 23, 2024, Licensee failed to properly remediate the Above Action Level (AAL) event, in violation of Board Policy 2023-09.

3. The Board and Licensee acknowledge and agree that based upon the information described in Paragraph 2 the Board could find the Licensee in violation of 247 Mass. Code Regs. 8.00 and Board Policy 2023-09 warranting disciplinary action by the Board under Mass. Gen. Laws ch. 112, §§ 42A, 61 and 247 Mass. Code Regs. 10.03(1)(a) & (m).
4. Licensee agrees that the Board shall impose a REPRIMAND on its license based on the facts described in Paragraph 2, effective as of the date on which the Board signs this Agreement (Effective Date).

Radioisotope Life Sciences
NU00023
PHA-2024-0089 & PHA-2024-0138

5. The Board agrees that in return for the Licensee's execution and successful compliance with all the requirements of this Agreement, the Board will not prosecute the Complaint.
6. Licensee understands that it has a right to formal adjudicatory hearing concerning the Complaint and that during said adjudication the Licensee would possess the right to confront and cross-examine witnesses, to call witnesses, to present evidence, to testify on its own behalf, to contest the allegations, to present oral argument, to appeal to the courts, and all other rights as set forth in the Massachusetts Administrative Procedures Act, Mass. Gen. Laws ch. 30A, and the Standard Adjudicatory Rules of Practice and Procedure, 801 Mass. Code Regs. 1.01 *et seq.* The Licensee further understands that by executing this Agreement the Licensee is knowingly and voluntarily waiving its right to a formal adjudication of the Complaint.
7. The Licensee acknowledges that it has been at all times represented by Counsel or otherwise free to seek and use legal counsel in connection with the Complaint and this Agreement.
8. The Licensee acknowledges that after the Effective Date, the Agreement constitutes a public record of disciplinary action by the Board subject to the Commonwealth of Massachusetts' Public Records Law, Mass. Gen. Laws ch. 4, § 7. The Board may forward a copy of this Agreement to other licensing boards, law enforcement entities, and other individuals or entities as required or permitted by law.
9. The Licensee understands and agrees that entering into this Agreement is a voluntary and final act and not subject to reconsideration, appeal or judicial review.
10. The individual signing this Agreement certifies that they are authorized to enter into this Agreement on behalf of the Licensee, and that they have read this Agreement.

4-9-25
Date


(signature)

Christie Nguyen
(print name)

Michael J. Godek, R.Ph.
Michael Godek, R. Ph.
Executive Director
Board of Registration in Pharmacy

04/10/2025
Effective Date of Reprimand Agreement

Radioisotope Life Sciences
NU00023
PHA-2024-0089 & PHA-2024-0138

Fully Signed Agreement Sent to Licensee on _____ by Certified Mail
No. _____